Financial Data and Key Metrics Changes - Revenue for Q2 2023 was $793.3 million, an increase of 9.0% year-over-year, with non-acquired revenue up 8.7% [18] - Adjusted EBITDA for the quarter was $171 million, reflecting a 14% increase year-over-year and an adjusted EBITDA margin of 21.6% [20] - Cash flow from operations was $86.3 million, with free cash flow for the first half of the year at $54.8 million [21] Business Line Data and Key Metrics Changes - Sleep revenue reached $303 million, a 16% increase year-over-year, driven by a 41% growth in PAP equipment patient census and an 11% increase in resupply orders [19] - Respiratory revenue was $154 million, up 13% year-over-year, marking the strongest patient acquisition quarter since Q4 2021 [19] - Diabetes revenue increased by 2% year-over-year, with a 13% rise in CGM patient census offsetting declines in pump orders [20] Market Data and Key Metrics Changes - Government-sponsored payers now account for 77% of the CGM census, an increase of 900 basis points year-over-year [12] - The company is seeing stabilization in the length of time patients are on oxygen and vents, which had decreased during the pandemic [9] Company Strategy and Development Direction - The company is focusing on enhancing its diabetes business, particularly in the government sector, where CGM and pump markets are expanding [11] - A new relationship with Humana aims to provide home medical equipment to Medicare Advantage members, which is expected to enhance patient care and operational metrics [14] - The company is committed to achieving $25 million in cost savings through operational improvements and technology investments [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate inflationary pressures through technology and process improvements [15] - The outlook for Q3 anticipates revenue growth of just over 5% year-over-year, with adjusted EBITDA margins expected to remain consistent with Q2 [22] - Management is optimistic about the operational improvements and the impact of the Humana agreement in the second half of the year [23] Other Important Information - The company is undergoing a transition in leadership with Crispin Teufel set to join as the new CEO [6] - The company has implemented a full warehouse management system to improve efficiency and reduce costs [39] Q&A Session Summary Question: What are the normalized growth rates for the diabetes business? - Management expects mid to upper single-digit growth for the diabetes product line by 2025, with modest low-single-digit growth anticipated for the remainder of 2023 [26] Question: How will Philips' return to the market affect margins and growth? - Management believes Philips' reentry will be beneficial for the market, but does not expect significant changes to their current supply chain or pricing dynamics [29] Question: What is the expected benefit of the Humana contract? - The Humana contract is expected to contribute to sequential growth in sleep, respiratory, and HME categories, although specific revenue expectations are not yet available [32] Question: What is the outlook for equipment buy-ins related to the Humana contract? - Management is confident that the revenue from the Humana contract will align with existing CapEx projections and will not require significant additional investment [35] Question: What is the status of the warehouse system upgrades? - The company has successfully integrated a new warehouse management system, which is expected to enhance efficiency and reduce costs moving forward [37] Question: What is the outlook for Medicare rates and competitive bidding? - Management believes competitive bidding will not disappear and expects future announcements regarding the program, but timing remains uncertain [60]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38399 AdaptHealth Corp. (Exact name of registrant as specified in its charter) Delaware 82-3677704 (State of Other Jurisdiction of incorporation or Organization) (I.R.S. Emp ...

AdaptHealth Corp. (NASDAQ:AHCO) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET Company Participants Chris Joyce - General Counsel Richard Barasch - Chairman Steve Griggs - Chief Executive Officer Josh Parnes - President Jason Clemens - Chief Financial Officer Conference Call Participants Brian Tanquilut – Jefferies Kevin Caliendo - UBS Philip Chickering - Deutsche Bank Joanna Gajuk - Bank of America Richard Close - Canaccord Operator Good day, everyone and welcome to today's AdaptHealth 1Q 2023 Ea ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 OR FORM 10-Q o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Commission file number: 001-38399 AdaptHealth Corp. (Exact name of registrant as specified in its charter) (State of Other Jurisdiction of incorporation or Organization) (I.R.S. Employer Identificatio ...

Adapthealth Corp (NASDAQ:AHCO) Q4 2022 Earnings Conference Call February 28, 2023 8:30 AM ET Company Participants Christopher Joyce - General Counsel & Secretary Stephen Griggs - CEO & Director Joshua Parnes - President & Director Jason Clemens - CFO & Principal Accounting Officer Conference Call Participants Philip Chickering - Deutsche Bank Joanna Gajuk - Bank of America Merrill Lynch Mathew Blackman - Stifel, Nicolaus & Company Operator Ladies and gentlemen, thank you for joining us this morning for the ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38399 AdaptHealth Corp. (Exact name of registrant as specified in its charter) Delaware 82-3677704 (State of Other Jurisdiction of incorporation or Organizatio ...

AdaptHealth Corp. (NASDAQ:AHCO) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Christopher Joyce - General Counsel Stephen Griggs - CEO Joshua Parnes - President Jason Clemens - CFO Conference Call Participants Taji Phillips - Jefferies Pito Chickering - Deutsche Bank Kevin Caliendo - UBS Richard Close - Canaccord Genuity Joanna Gajuk - Bank of America Eric Coldwell - Robert W. Baird Whit Mayo - SVB Securities Operator Greetings, and welcome to AdaptHealth's Third Quarter ...

Financial Data and Key Metrics Changes - AdaptHealth reported record revenues of $727.6 million for Q2 2022, representing a year-over-year growth of 17.9% [16] - The company maintained its full-year guidance for revenue between $2.840 billion and $3.040 billion and adjusted EBITDA of $615 million to $675 million [21] - Free cash flow for the quarter was $26.3 million, exceeding expectations [19] Business Line Data and Key Metrics Changes - The Sleep business saw a 16% increase in census from February 2022, with strong growth in PAP rental and resupply [9] - The diabetes business experienced a year-to-date non-acquired growth of 17%, although growth was flat for the quarter [10] - Non-acquired growth for the total company declined by 30 basis points for the quarter [17] Market Data and Key Metrics Changes - The company is largely insulated from higher interest rates, with over 75% of its debt being fixed [11] - Inflationary pressures and supply chain issues have impacted results, but the company has managed to stabilize gross margins [10][18] Company Strategy and Development Direction - AdaptHealth is focusing on leveraging technology to improve patient care and operational efficiencies, including e-prescribe and e-ordering platforms [12][13] - The company is pursuing value-based payment arrangements, having signed two new agreements with managed care payers [12] - Investments in technology are aimed at transforming the home medical equipment experience and improving patient satisfaction [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving guidance for the year despite inflation and supply chain challenges [8] - The backlog of patients has remained stable, with expectations for a successful third quarter as product availability improves [31] - Management is optimistic about the potential for further acquisitions as supply issues ease [33] Other Important Information - The company repurchased 199,000 shares for $3.4 million during the second quarter [20] - A Capital Markets Day is scheduled for September 16, where the company will present future targets and opportunities [22] Q&A Session Summary Question: What is driving the weakness in the diabetes segment? - Management noted that the lack of acquisitions in the first half of the year affected growth rates, but overall performance is in line with market expectations [26] Question: Can G&A expenses be reduced going forward? - Management indicated that planned investments in technology would not yield operating leverage until the end of next year, but they are confident in the long-term benefits [28] Question: How is the backlog of patients being managed? - Management stated that the backlog has remained stable, with expectations for improved setups in the third quarter as supply increases [31] Question: What is the expected organic growth for the Sleep business? - Management expressed confidence that the Sleep business would outperform expectations, contributing positively to overall growth [37] Question: What is the margin expansion outlook for the second half of the year? - Management indicated that margin expansion would be driven by increased rental revenue and operational efficiencies as the year progresses [52]